Arca
Skip to content
Tools
Tools

Primary sclerosing cholangitis

Drug research and approvals for primary sclerosing cholangitis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 32 studies of primary sclerosing cholangitis are recruiting on ClinicalTrials.gov, Health Canada has authorized 14 drug trials for it since 2013, and FDA has 0 approved and 18 open orphan designations naming it.

  • Recruiting worldwide: 32
  • Trials authorized in Canada: 14
  • FDA orphan approvals: 0
  • EU medicines: 0

Recruiting now

Newest posted first, of 32 recruiting on ClinicalTrials.gov ↗

Trials authorized in Canada

The 10 newest of 14; search them all in Canada trials
Nov 5, 2025A double-blind randomized placebo-controlled investigation of vancomycin efficacy in patients with ulcerative colitis and primary sclerosing cholangitis…VancomycinMcMaster UniversityPending
Dec 2, 2024A phase 2b/3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of aldafermin in subjects with…Aldafermin (NGM282)Ngm BiopharmaceuticalsPending
Dec 8, 2022A phase II, multicenter, double-blind, randomised, placebo-controlled study and open-label long term extension to evaluate the safety and efficacy of…Elafibranor (IPN60190)IpsenOngoing
Aug 3, 2022Randomized, double-blind, placebo-controlled study to evaluate the effects of EP547 in subjects with cholestatic pruritus due to primary biliary cholangitis or…EP547Escient Pharmceuticals IncClosed
Aug 19, 2021A randomized double-blind placebocontrolled study to evaluate the efficacy and safety of volixibat in the treatment of cholestatic pruritus in patients with…Volixibat (SHP626, LUM002)Mirum PharmaceuticalsOngoing
Jun 18, 2020A randomized, double-blind, dose-ranging, placebo-controlled, phase 2a evaluation of the safety, tolerability, and pharmacokinetics of PLN-74809 in…PLN-74809Pliant TherapeuticsClosed
Nov 6, 2019A proof-of-concept and dose-ranging study investigating the efficacy and safety of HTD1801 in adult subjects with primary sclerosing cholangitis (PSC)HTD1801 (berberine ursodeoxycholate)Hightide Biopharma Proprietary LimitedClosed
Jul 24, 2019A phase 2, randomized, double blind, placebo controlled, multiple center study to evaluate the safety, tolerability, and efficacy of seladelpar administered…SeladelparCymaBay TherapeuticsOngoing
May 2, 2019A phase 3, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, and efficacy of cilofexor in non-cirrhotic subjects with…Cilofexor (GS-9674)Gilead SciencesClosed
Sep 27, 2018A prospective, randomized, multi-centered, placebo-controlled, clinical trial of oral vancomycin in adults with primary sclerosing cholangitisVancomycinDr Johannes A (Bertus) EksteenPending

FDA orphan designations

Approved first, then open designations, newest first; 15 of 18
Jul 21, 2026VolixibatTreatment of primary sclerosing cholangitisMirum Pharmaceuticals, Inc.Designated
Jul 16, 2025ElafibranorTreatment of primary sclerosing cholangitisIPSEN Bioscience Inc.Designated
Apr 9, 2024Small molecule inhibitor of hyaluronan synthesisTreatment of primary sclerosing cholangitisHalo Biosciences, Inc.Designated
Dec 1, 2022Live biotherapeutic product consisting of a single…Treatment of Primary Sclerosing CholangitisLISCure Biosciences Inc.Designated
Nov 15, 20223-([3,3-dibutyl-7-(methylsulfanyl)-1,1-dioxo-5-phenyl-2,3,4,…Treatment of Primary Sclerosing CholangitisAlbireo ABDesignated
May 24, 2022Gly-Trp-Thr-Leu-Asn-Ser-Ala-Gly-Tyr-Leu-Leu-…Treatment of primary sclerosing cholangitisSterotherapeutics, LLCDesignated
Mar 28, 2022Beta-LapachoneTreatment of Primary Sclerosing Cholangitis (PSC)Curome Biosciences Co., Ltd.Designated
Sep 13, 20213-(4-((3-endo)-3-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxa…Treatment of Primary Sclerosing CholangitisCascade Pharmaceuticals, IncDesignated
Jun 24, 2021Norucholic acidTreatment of Primary Sclerosing CholangitisDr. Falk Pharma GmbHDesignated
Mar 4, 2020Glucagon-like peptide-1/Glucagon/Gastric inhibitory…Treatment of primary sclerosing cholangitisHanmi Pharmaceutical Company, Ltd.Designated
Oct 25, 20182-[3-(2-chloro-4-{[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-…Treatment of Primary Sclerosing Cholangitis (PSC)Gilead Sciences, Inc.Designated
Oct 11, 2018Monoclonal antibody targeting CCL24Treatment of primary sclerosing cholangitisChemomAb, Ltd.Designated
Jul 6, 20175-cholesten-3ß, 25-diol 3-sulfate sodium salt (25HC3S)Treatment of primary sclerosing cholangitis (PSC)DURECT CorporationDesignated
Jun 21, 2017(S)-3-((S)-2-(2-((2,6-difluorophenyl)amino)-2-oxoacetamido)p…Treatment of primary sclerosing cholangitis (PSC)Conatus PharmaceuticalsDesignated
Jun 15, 2017CotsiranibTreatment of primary sclerosing cholangitisSirnaomics, Inc.Designated

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.